MEDICAL TREATMENT IN EWING SARCOMA

Código QR

MEDICAL TREATMENT IN EWING SARCOMA

Guardado en:

Detalles Bibliográficos
Autor principal:	Roberto Luksch
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/c761da2a389c422ca2ed0082912f5dae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

PRIMARY EWING'S SARCOMA OF SPHENOID BONE EXTENDING TO BRAINSTEM; AN ORDINARY TUMOUR AT AN EXTRAORDINARY LOCATION AND INVOLVEMENT
por: Seda ŞAHİN, et al.
Publicado: (2021)

MEDICAL TREATMENT IN HODGKIN LYMPHOMA
por: Nilgun Kurucu
Publicado: (2021)

CAN SERUM KL-6 LEVEL BE USED AS A MARKER IN LUNG METASTASIS OF BONE SARCOMAS?
por: Turan BAYHAN, et al.
Publicado: (2021)

GVHD TREATMENT
por: Elif BirtaşAteşoğlu
Publicado: (2021)

Azacytidine Treatment for VEXAS Syndrome
por: Marc H. G. P. Raaijmakers, et al.
Publicado: (2021)

TARGETED THERAPY IN AML TREATMENT
por: Giovanni Martinelli
Publicado: (2021)

Ruxolitinib as an emerging treatment in myelofibrosis
por: Emanuel RM, et al.
Publicado: (2013)

Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma
por: Yoshimitsu M, et al.
Publicado: (2014)

Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
por: Harnicar S, et al.
Publicado: (2014)

OUTCOME OF SPLENECTOMY IN THE TREATMENT OF ITP – ONE CENTER EXPERIENCE
por: Weronika Lebowa, et al.
Publicado: (2021)

Profile of elotuzumab and its potential in the treatment of multiple myeloma
por: Liu YC, et al.
Publicado: (2014)

POST-TREATMENT NUTRITIONAL STATUS OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
por: Akbar Akbarov, et al.
Publicado: (2021)

TREATMENT OF RELAPSED, REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Ebru Pekgüç, et al.
Publicado: (2021)

EVALUATION OF VACCINATION RESPONSE IN CHILDREN AFTER TREATMENT FOR ACUTE LEUKEMIA
por: Elif KILIC KONTE, et al.
Publicado: (2021)

INAPPROPRIATE ADH SYNDROME OCCURING DURING B-ALL TREATMENT
por: Merih Reis Aras, et al.
Publicado: (2021)

Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
por: Gupta VA, et al.
Publicado: (2013)

Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
por: McKinney MS, et al.
Publicado: (2014)

Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias
por: Thomas X
Publicado: (2012)

T-ACUTE MYELOID LEUKEMIA CASE THOUGHT TO BE ASSOCIATED WITH RADIOIODINE (I¹³¹) TREATMENT
por: Merih Reis Aras, et al.
Publicado: (2021)

Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia
por: O&#39;Brien S, et al.
Publicado: (2012)

Reduced intensity treatment in early-stage Hodgkin&rsquo;s lymphoma
por: Armitage JO, et al.
Publicado: (2011)

Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose
por: Waclaw J, et al.
Publicado: (2015)

Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
por: Thomas X
Publicado: (2014)

RETROSPECTIVE EVALUATION OF PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING VENATOCLAX-BASED TREATMENT
por: EMINE DURAK, et al.
Publicado: (2021)

HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE
por: Nur OLGUN, et al.
Publicado: (2021)

THE EFFECT OF BISPHOSPHONATE USE ON TREATMENT RESPONSE AND OVERALL SURVIVAL IN MULTIPLE MYELOMA PATIENTS
por: Ayşe Uysal, et al.
Publicado: (2021)

ETIOLOGY, TREATMENT AND FOLLOW-UP OF THROMBOSIS IN CHILDREN, ONE CENTER PROSPECTIVE TRIAL
por: Yunus Murat Akcabelen, et al.
Publicado: (2021)

Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
por: Illidge T, et al.
Publicado: (2012)

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
por: Meletios A. Dimopoulos, et al.
Publicado: (2021)

Trends in the treatment of cutaneous T-cell lymphoma &ndash; critical evaluation and perspectives on vorinostat
por: Zhang CL, et al.
Publicado: (2012)

Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future
por: Flowers CR, et al.
Publicado: (2012)

mTOR inhibitor in the treatment of Hodgkin&rsquo;s lymphoma: a case report
por: Provencio M., et al.
Publicado: (2011)

De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment
por: Despina Fotiou, et al.
Publicado: (2021)

ANTI-CD52 TREATMENT EXPERIENCE IN A T-CELL PROLYMPHOCYTIC LEUKEMIA PATIENT:CASE REPORT
por: Senem MARAL, et al.
Publicado: (2021)

A CHALLENGE IN PEDIATRIC ACUTE LEUKEMIA TREATMENT: UNEXPECTED, PROLONGED CYTOPENIA. IS IT BE CALLLED ‘INCOMPLETE HLH’?
por: Ersin Toret, et al.
Publicado: (2021)

Summary of Joint European Hematology Association (EHA) and EuroBloodNet Recommendations on Diagnosis and Treatment of Methemoglobinemia
por: Achille Iolascon, et al.
Publicado: (2021)

Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment
por: Pujals A, et al.
Publicado: (2015)

The Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular seeks the implementation of, and access to, the CAR-T cell treatment in Brazil
por: Dante Mário Langhi Junior, et al.
Publicado: (2021)

VENETOCLAX AZACITIDINE COMBINATION THERAPY IN FIRST-LINE TREATMENT OF ACUTE MYELOID LEUKEMIA PATIENTS: A SINGLE CENTER EXPERIENCE
por: Melda Cömert, et al.
Publicado: (2021)

Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib
por: Shoumariyeh K, et al.
Publicado: (2014)